Steadybase.

Polaryx Therapeutics, Inc.

Website Investor relations LinkedIn Latest 10-K
  • PLYX ยท Nasdaq
  • Pharmaceutical Preparations
  • Paramus, NJ
  • 11 employees
  • CIK 0002075320

Updated from SEC filings through

Top things to know

Executives

Polaryx Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Paramus, NJ. It trades as PLYX on Nasdaq. It reported about 11 employees.

Five-year financials

MetricFY2025FY2024
Revenue Not on file Not on file
Operating income -$7.8M
10-K, 2026-03-24
-$4.4M
10-K, 2026-03-24
SG&A $1.6M
10-K, 2026-03-24
$1.5M
10-K, 2026-03-24
Net income -$9.0M
10-K, 2026-03-24
-$30.4M
10-K, 2026-03-24

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Alex Keun Mo Yang Alex Keun Mo Yang Chief Executive Officer Form 4, May 28, 2026
G. Michael Landis G. Michael Landis Chief Financial Officer Form 4, February 20, 2026
Lisa L. Bollinger, M.D. Lisa L. Bollinger, M.D. Chief Medical Officer 10-K, March 24, 2026
Andrew John O. Chief Investment Officer Form 3, January 29, 2026
Francis A. Braun III Director 10-K, March 24, 2026
Mitchel Berger, M.D. Director 10-K, March 24, 2026

What Polaryx Therapeutics, Inc. does

PLX-200 (gemfibrozil), our most advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed, reformulated drug that we are pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. We are advancing PLX-200 through a Phase 2 proof-of-concept basket trial, which we refer to as SOTERIA (PLX-200-600), and expect to initiate this trial in the second half of 2026.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 49.8 million (as of October 31, 2026) 10-Q, November 12, 2026
Public float $0 (as of June 30, 2025) 10-K, March 24, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 12, 2026
Latest proxy statement Meeting September 10, 2026 (filed July 28, 2026) DEF 14A, July 28, 2026
Auditor Grant Thornton LLP (Edison, New Jersey) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
May 27, 2026 Alex Keun Mo Yang
Chief Executive Officer
Buy 88,453 $360K Form 4, May 28, 2026
May 27, 2026 Partners Healthcare Ltd Mstone
Director
Buy 88,453 $360K Form 4, May 28, 2026
February 18, 2026 G. Michael Landis
Chief Financial Officer
Buy 2,867 $8K Form 4, February 20, 2026

Recent 8-K events

Frequently asked questions about Polaryx Therapeutics, Inc.

What does Polaryx Therapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "PLX-200 (gemfibrozil), our most advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed, reformulated drug that we are pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. We are advancing PLX-200 through a Phase 2 proof-of-concept basket trial, which we refer to as SOTERIA (PLX-200-600), and expect to initiate this trial in the second half of 2026."
How many employees does Polaryx Therapeutics, Inc. have?
About 11 as of December 31, 2025, as stated in its annual report.
Who is the CFO of Polaryx Therapeutics, Inc.?
G. Michael Landis, Chief Financial Officer, as named in a 4 filed February 20, 2026.
Where is Polaryx Therapeutics, Inc. headquartered?
Paramus, NJ.
What is Polaryx Therapeutics, Inc.'s stock ticker?
PLYX on Nasdaq.
What industry is Polaryx Therapeutics, Inc. in?
Pharmaceutical Preparations, SIC code 2834.
What is Polaryx Therapeutics, Inc.'s website?
polaryx.com. Investor relations: https://investors.polaryx.com.
When does Polaryx Therapeutics, Inc. report earnings next?
February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Polaryx Therapeutics, Inc. a public company?
Yes. Polaryx Therapeutics, Inc. files with the SEC under CIK 0002075320 and trades as PLYX.
Who audits Polaryx Therapeutics, Inc.?
Grant Thornton LLP, Edison, New Jersey, as named in its latest annual report (10-K).
How many shares of Polaryx Therapeutics, Inc. are outstanding?
49.8 million shares as of October 31, 2026, from its 10-Q filed November 12, 2026.
What is Polaryx Therapeutics, Inc.'s public float?
$0 as of June 30, 2025, as reported on the cover of its 10-K filed March 24, 2026.
How many business segments does Polaryx Therapeutics, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
When is Polaryx Therapeutics, Inc.'s annual shareholder meeting?
September 10, 2026, per its proxy statement (DEF 14A) filed July 28, 2026.
Have Polaryx Therapeutics, Inc. insiders traded stock recently?
Since February 18, 2026, officers and directors reported 0 open-market sales and 3 purchases worth about $728K on Forms 4 and 5. The most recent: Alex Keun Mo Yang (Chief Executive Officer) bought 88,453 shares on May 27, 2026.